Status: Recruiting
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria as assessed by blinded independent central review (BICR).
Participants needed: 735
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Merck Sharp & Dohme LLCUpdated: May 18, 2026Locations: 54
Eligibility criteria
Confirmed diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma (... [+12]
Has an active hepatitis B virus/ hepatitis C virus (HBV/HCV) infection [+15]